| 1.12 -0.97 (-46.41%) | 03-27 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 2.72  |
1-year : | 3.6 |
| Resists | First : | 2.33 |
Second : | 3.08 |
| Pivot price | 2.28 |
|||
| Supports | First : | 1.11 |
Second : | 0.92 |
| MAs | MA(5) : | 1.98 |
MA(20) : | 2.39 |
| MA(100) : | 3.1 |
MA(250) : | 3.54 |
|
| MACD | MACD : | -0.3 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 10.7 |
D(3) : | 17.9 |
| RSI | RSI(14): 14.9 |
|||
| 52-week | High : | 5.74 | Low : | 1.11 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ LTRN ] has closed below the lower bollinger band by 27.3%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 94% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.42 - 2.44 | 2.44 - 2.45 |
| Low: | 1.09 - 1.1 | 1.1 - 1.11 |
| Close: | 1.11 - 1.12 | 1.12 - 1.13 |
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-300 as a combination therapy for non or never-smokers with non-small cell lung cancer adenocarcinoma. In addition, its preclinical development drug candidate is LP-184, an alkylating agent that damages DNA in cancer cells that overexpress certain biomarkers or that harbor mutations in DNA repair pathways. Further, the company operates ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Additionally, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Fri, 27 Mar 2026
Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report - Stock Titan
Fri, 27 Mar 2026
Lantern Pharma Inc expected to post a loss of 46 cents a share - Earnings Preview - TradingView
Fri, 27 Mar 2026
Lantern Pharma CEO Steps Down Amid Financial Oscillation - timothysykes.com
Fri, 27 Mar 2026
Why Did LTRN Stock Surge 18% In Pre-Market Today? - Stocktwits
Mon, 23 Mar 2026
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2025 Operating & Financial Results on March - PharmiWeb.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 11 (M) |
| Shares Float | 9 (M) |
| Held by Insiders | 13.6 (%) |
| Held by Institutions | 19.9 (%) |
| Shares Short | 308 (K) |
| Shares Short P.Month | 313 (K) |
| EPS | -1.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.87 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -56 % |
| Return on Equity (ttm) | -104.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.76 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -17 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.64 |
| PEG Ratio | 0 |
| Price to Book value | 1.28 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.75 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|